BR0315084A - Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina - Google Patents

Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina

Info

Publication number
BR0315084A
BR0315084A BR0315084-4A BR0315084A BR0315084A BR 0315084 A BR0315084 A BR 0315084A BR 0315084 A BR0315084 A BR 0315084A BR 0315084 A BR0315084 A BR 0315084A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
hemihydrate
sibutramine
methanesulfonate hemihydrate
sibutramine methanesulfonate
Prior art date
Application number
BR0315084-4A
Other languages
English (en)
Inventor
Jae-Heon Lee
Gha-Seung Park
Jae-Cheol Lee
Han-Kyong Kim
Young-Kil Chang
Gwan-Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2003-0053752A external-priority patent/KR100536750B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR0315084A publication Critical patent/BR0315084A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO HEMIIDRATO CRISTALINO DE METANOSSULFONATO DE SIBUTRAMINA". A presente invenção está relacionada a uma composição farmacêutica para tratar ou prevenir obesidade, compreendendo novo hemiidrato cristalino de metanossulfonato de sibutramina de fórmula (I). O hemiidrato cristalino de metanossulfonato de sibutramina de acordo com a presente invenção tem uma solubilidade muito superior em água, e aprimorada estabilidade sob uma condição de alta umidade/temperatura, como comparada com o monoidrato de cloridrato de sibutramina.
BR0315084-4A 2002-10-05 2003-09-25 Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina BR0315084A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20020060798 2002-10-05
KR10-2003-0053752A KR100536750B1 (ko) 2002-10-05 2003-08-04 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
PCT/KR2003/001955 WO2004030663A1 (en) 2002-10-05 2003-09-25 Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Publications (1)

Publication Number Publication Date
BR0315084A true BR0315084A (pt) 2005-08-16

Family

ID=36147018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315084-4A BR0315084A (pt) 2002-10-05 2003-09-25 Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina

Country Status (14)

Country Link
US (1) US6900245B2 (pt)
EP (1) EP1545484A4 (pt)
JP (1) JP4278652B2 (pt)
AU (1) AU2003264968B2 (pt)
BR (1) BR0315084A (pt)
CA (1) CA2501321C (pt)
HK (1) HK1083741A1 (pt)
HR (1) HRP20050307A2 (pt)
MX (1) MXPA05003355A (pt)
NO (1) NO20052222L (pt)
NZ (1) NZ538966A (pt)
PL (1) PL375032A1 (pt)
RU (1) RU2290924C2 (pt)
WO (1) WO2004030663A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
EP1846359A4 (en) * 2005-01-06 2010-03-31 Cj Cheiljedang Corp INORGANIC ACID SALTS OF SIBUTRAMINE
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
JP4934293B2 (ja) * 2005-07-05 2012-05-16 コスモ石油株式会社 植物活力剤組成物
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
KR100806673B1 (ko) 2006-06-23 2008-03-03 주식회사 대희화학 결정상 시부트라민 프리베이스의 제조방법
KR20100088992A (ko) * 2009-02-02 2010-08-11 주식회사 대희화학 (ｒ)-시부트라민 염 및 그의 제조방법
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
CN102786444A (zh) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 一种西布曲明类似物的磺酸盐的制备方法
KR102425265B1 (ko) 2014-08-25 2022-07-26 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2098302B (en) * 1981-05-13 1985-02-06 Fort Vale Eng Ltd Improvements in lids for pressure vessels
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
AU3757800A (en) * 1999-03-19 2000-10-09 Abbott Gmbh & Co. Kg Method of controlling weight gain associated with therapeutic drugs
US6376551B1 (en) * 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3757300A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating anxiety disorders
CA2367022A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sleep apnoea
AU3894600A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6232347B1 (en) * 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
AU2002210816A1 (en) * 2000-11-02 2002-05-15 Torrent Pharmaceuticals Ltd Process for preparation of beta-phenethylamine derivative

Also Published As

Publication number Publication date
US20040068018A1 (en) 2004-04-08
RU2005109560A (ru) 2005-09-20
HK1083741A1 (en) 2006-07-14
EP1545484A1 (en) 2005-06-29
CA2501321C (en) 2008-07-08
HRP20050307A2 (en) 2006-12-31
EP1545484A4 (en) 2010-01-13
JP2006506449A (ja) 2006-02-23
AU2003264968A1 (en) 2004-04-23
RU2290924C2 (ru) 2007-01-10
AU2003264968B2 (en) 2006-03-16
PL375032A1 (en) 2005-11-14
CA2501321A1 (en) 2004-04-15
NZ538966A (en) 2006-11-30
US6900245B2 (en) 2005-05-31
JP4278652B2 (ja) 2009-06-17
NO20052222L (no) 2005-05-06
MXPA05003355A (es) 2005-10-18
WO2004030663A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0315084A (pt) Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BRPI0506906A (pt) composição farmacêutica sólida estável, processos para a estabilização de um sal, e para a preparação de um sal cristalino, e, sal cristalino
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
WO2006062984A3 (en) Inhibitors of protein kinases
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
SE0202463D0 (sv) Novel compounds
NO20064282L (no) Morfolinforbindelser
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
TW200630374A (en) Thiazolyldihydroindazoles
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
HK1048474A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones.
WO2007126900A3 (en) Antifungal agents
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
GB0314967D0 (en) Piperazine derivatives
BRPI0508927A (pt) compostos úteis para o tratamento de doenças
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2023007287A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas.
DE602006007483D1 (pt)
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/13, A61P 3/00

Ipc: A61K 31/13 (2011.01), A61P 3/00 (2011.01)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.